T-cell lymphoma treatments

Patent metadata

Field	Value
Publication number	US-11766442-B2
Application number	US-201816622581-A
Country	US
Kind code	B2
Filing date	Jun 15, 2018
Priority date	Jun 16, 2017
Publication date	Sep 26, 2023
Grant date	Sep 26, 2023

Abstract

Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

First claim

What is claimed is:

1. A method for treating cutaneous T-cell lymphoma (CTCL) in a subject in need thereof, comprising administering to the subject a compound having the following structure:

2. The method of claim 1 ,
wherein the cutaneous T-cell lymphoma is Sezary syndrome, mycosis fungoides, folliculotropic mycosis fungoides, pagetoid reticulosis, granulomatous slack skin, primary cutaneous CD30+ T-cell lymphoproliferative disorders, lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, primary cutaneous γδ T-cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, or primary cutaneous CD4+ small/medium T-cell lymphoma.

3. The method of claim 1 , wherein the cutaneous T-cell lymphoma is associated with at least one of the following conditions: smoking, obesity, infection, HIV, Epstein-Barr virus, human T-lymphotropic virus, Helicobacter pyroli infection, chronic Helicobacter pyroli infection, exposure to chemicals, exposure to insecticides, exposure to pesticides, use of immunosuppressant drugs, weakened immune system, genetic disorders, previous chemotherapy, and previous radiation therapy.

4. The method of claim 1 , further comprising administering to the subject an additional therapeutic agent used in the treatment of T-cell lymphoma,
wherein the additional therapeutic agent is alemtuzumab, bendamustine, bexarotene, bleomycin, bortezomib, brentuximab vedotin, carboplatin, carfilzomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, dazatinib, denileukin diftitox, dexamethasone, doxorubicin, etoposide, everolimus, fludarabine, forodesine, gemcitabine, hydroxydaunorubicin, ifosfamide, imiquimod, interferons, lenalidomide, liposomal doxorubicin, mechlorethamine, methotrexate, methylprednisolone, nelfinavir, oral corticosteroids, panobinostat, pentostatin, pralatrexate, prednisone, prednisolone, psoralen, retinoids, resiquimod, rituximab, romidepsin, SGX301, temsirolimus, topical corticosteroids, vinblastine, vincristine, vinorelbine, vorinostat, or a combination thereof.

5. The method of claim 1 , wherein the compound is:

Assignees

• Hope City

Inventors

• Horne David
• Nam Sangkil

Classifications

• A61K31/548 Primary

  having two or more sulfur atoms in the same ring · CPC title

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/554

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title